- Language: English
- 1040 Pages
- Published: December 2009
- Region: Global
New Generation Vaccines. Edition No. 4
- Published: December 2009
- Region: Global
- 1040 Pages
- Informa Healthcare
Highlighting the latest activities and initiatives of prominent organizations working in the vaccine industry such as the Bill and Melinda Gates Foundation, The Global Alliance for Vaccines and Immunization, WHO, UNICEF, the World Bank, New Generation Vaccines, Fourth Edition, details steps developing countries have taken toward research, development, manufacture, and regulation of several new vaccines for widespread use.
This text will:
cover the current state-of-the-art techniques in vaccine development – including the successes and the failures
trace vaccine development from the bench to public health with regard to both FDA and European Union regulations
investigate improved methods for immunizing large populations, and the use of needless vaccinations
discuss the advancements in the heavily government-funded areas for developing vaccines against potential bioterror and infectious disease agents as well as the immunization of large population bases for diseases like: Anthrax, Smallpox, Ebola, West Nile, SARS, and others
Updated throughout with new cutting-edge information on recent breakthroughs and developments.
NEW TO GENERATION VACCINES, FOURTH EDITION:
highlights the latest activities of prominent organizations in the vaccine industry
covers the current techniques in vaccine development
investigates improved methods for immunizing large populations SHOW LESS READ MORE >
Vaccines and Vaccination in Historical Perspective. An Overview of Biotechnology in Vaccine Initial Clinical Evaluation of New Vaccine Candidates: Investigators’ Perspective of Phase I and II Clinical Trials of Safety, Immunogenicity & Preliminary Efficacy Development. Clinical vaccine trials in developing countries Long-Term Evaluation of Vaccine Protection: Methodological Issues for Phase III and IV Studies (including designs to measure herd immunity). Ethical Considerations in the Conduct of Vaccine Trials in Developing Countries Vaccine Economics: From Candidates to Commercialized Products in the Developing World (will include new G8 financing mechanisms). Development and Supply of Vaccines: An Industry Perspective Reaching Every Child – Achieving Equity in Global Immunization A Paradigm for International Cooperation: the Global Alliance for Vaccines and Immunization (GAVI) and the Vaccine Fund Economic Analyses of Vaccines and Vaccination Programs The Role of the Food and Drug Administration and other Industrialized Country Regulatory Agencies in Vaccine Testing and Licensure Strengthening Regulatory Agencies in Developing Countries Developing Safe Vaccines A Primer on Large-Scale Manufacture of Modern Vaccines. Polio Eradication: Ever Closer to a Worthy but Elusive Goal Full Genome Sequence Analysis (Data Mining) and Bioinformatics Overview of Reverse Vaccinology Recent Advances in Immunology that Impact Vaccine Development How the Innate Immune System Affects Adaptive Immune Responses to Vaccines Immunodominance, Deceptive Imprinting & B Cell Mimotopes Standardization and High-Throughput Measurement of T-Cell and B-Cell Responses to Vaccines The Challenge of Inducing Protection in Very Young Infants and the Elderly. Vaccination and Autoimmunity An Overview of Adjuvants for the Future Immune-Enhancing Sequences (CpG Motifs), Cytokines, and Other Immunomodulatory Moieties. Use of Genetically Detoxified Mutants of Cholera and Escherichia coli Heat-Labile Enterotoxins as Mucosal Adjuvants Recent Developments in Antigen Delivery Systems Virus-like Particle (VLP) Vaccines. Plants as a Production and Delivery Vehicle for Orally Delivered Subunit Vaccines Lipid-based Self-Adjuvanting Vaccines Antibodies, Ligands and Other Mechanisms of Specifically Targeting Dendritic Cells as a Way of Enhancing Immune Responses to Vaccines against Infectious Diseases Vaccinia Virus and Other Poxviruses as Live Vectors Replication-Deficient and Competent Adenovirus Recombinants as Vaccine Vectors RNA Virus Replicon Vaccines Attenuated Salmonella and Shigella as Live Vectors Carrying Either Prokaryotic or Eukaryotic Expression Systems. DNA Vaccines (Overview) Mucosal Immunization and Needle-Free Injection Devices Administration of Attenuated Measles Vaccine by Small Particle Aerosol Devices Immunization of the Skin as an Immunologic Organ Combination Parenteral Vaccines for Routine Infant Immunization Heterogeneity of Pediatric Immunization Schedules in Industrialized Countries Meningococcal Conjugate and Protein-Based Vaccines (quadrivalent; WHO-PATH A conjugate). The Post-Licensure Impact of Serogroup C Neisseria meningitidis Conjugate Vaccines Impact of Hib conjugate in industrialized countries: successes and resurgences Hib disease burden and impact of programmatic infant immunization in developing countries Pneumococcal Protein-Polysaccharide Conjugate Vaccines Pneumococcal Common Proteins & Other Vaccine Strategies Polysaccharide-Based Conjugate Vaccines for Enteric Bacterial Infections: Typhoid Fever, NonTyphoidal Salmonellosis, Shigellosis and E. coli O157 Attenuated Strains of Salmonella enterica serovar Typhi as Live Oral Vaccines Against Typhoid Fever Oral Live and Non-Living Cholera Vaccines. Novel Vaccines Against Tuberculosis New Approaches to Interpandemic and Pandemic Influenza Vaccines Chimeric Vaccines Against Japanese Encephalitis, Dengue and West Nile. Vaccines against Rotavirus Virus Heterologous Prime-Boost Measles Vaccine for Immunizing Infants in Developing Countries Who Are Too Young to Receive Currently Licensed Measles Vaccines Challenges and Current Strategies in the Development of HIV/AIDS Vaccines Vaccine Strategies to Prevent Dengue Fever Vaccines.
Myrone M. Levine
Myron M. Levine University of Maryland, Baltimore, USA.
Gordon Dougan The Sanger Institute, Hinxton, Cambridge, UK.
Michael F. Good Queensland Institute of Medical Research, Brisbane, Australi.
Margaret A. Liu ProTherImmune & Karolinska Institute, Lafayette, California,.
Gary J. Nabel National Institutes of Health, Bethesda, Maryland, USA.
James P. Nataro University of Maryland, Baltimore, USA.
Rino Rappuoli Novartis Vaccines & Diagnostics s.r.l., Sienne SI, Italy.